The substantial differences between trypanosomal and leishmanial DNA topoisomerase IB concerning to their homologues in mammals have provided a new lead in the study of the structural determinants that can be effectively targeted. Leishmania donovani, the causative agent of visceral leishmaniasis, contains an unusual heterodimeric DNA topoisomerase IB. The catalytically active enzyme consists of a large subunit (LdTopIL), which contains the non-conserved N-terminal end and the phylogenetically conserved “core” domain, and of a small subunit (LdTopIS) which harbors the C-terminal region with the characteristic tyrosine residue in the active site. Heterologous co-expression of LdTopIL and LdTopIS genes in a topoisomerase I deficient yeast strain, reconstitutes a fully functional enzyme LdTopIL/S which can be used for structural studies. An approach by combinatorial cloning of deleted genes encoding for truncated versions of both subunits was used in order to find out structural insights involved in enzyme activity or protein-protein interaction. The role played by the non-conserved N-terminal extension of LdTopIL in both relaxation activity and CPT sensitivity has been examined co-expressing the full-length LdTopIS and a fully active LdTopIΔS deletion with several deletions of LdTopIL lacking growing sequences of the N-terminal end. The sequential deletion study shows that the first 26 amino acids placed at the N-terminal end and a variable region comprised between Ala548 to end of the C-terminal extension of LdTopIL were enzymatically dispensable. Altogether this combinatorial approach provides important structural insights of the regions involved in relaxation activity and for understanding the atypical structure of this heterodimeric enzyme.
Citation: Díaz González R, Pérez Pertejo Y, Ordóñez D, Balaña-Fouce R, Reguera RM (2007) Deletion Study of DNA Topoisomerase IB from Leishmania donovani: Searching for a Minimal Functional Heterodimer. PLoS ONE 2(11): e1177. https://doi.org/10.1371/journal.pone.0001177
Academic Editor: Jennifer Keiser, Swiss Tropical Institute, Switzerland
Received: July 16, 2007; Accepted: October 26, 2007; Published: November 14, 2007
Copyright: © 2007 Diaz Gonzalez et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This research was supported by Ministerio de Ciencia y Tecnología (grants BMC2002-04107-C02-02, AGL2003 06976/GAN and AGL2006-07420/GAN) and Instituto de Salud Carlos III (grant PI06302) from “Ministerio de Sanidad y Consumo” from Spain.
Competing interests: The authors have declared that no competing interests exist.
Leishmania donovani is the etiological agent of visceral leishmaniasis, a very serious disease transmitted by the bite of female sandflies of the Phlebotomine and Lutzomyia genera, characterized by fever, swelling of the spleen and liver and anaemia which may be fatal if not diagnosed and treated on time . It is well-established the role played by the host immune system in resistance and healing of this disease but no effective vaccine has been developed at present. Current pharmacopoeia against leishmaniasis includes amongst others; pentavalent antimonium salts, macrolides, aromatic diamidines and recently alquilphospholipids. Most of them are plenty of undesirable side effects, or require parental administration and long-term treatments .
DNA topoisomerases are striking candidate targets for leishmaniasis therapy . These enzymes catalyze changes in the topological state of duplex DNA during replication, transcription, recombination and DNA repair processes, by introducing transient single strain breaks in the nucleic acid backbone. Trypanosomatid type IB DNA topoisomerases differ from their homologues in their oligomeric nature. These enzymes are AB heterodimers with the genes encoding each protomer located on different chromosomes –. Genetic analyses identified a gene for a large subunit, namely LdTopIL, on L. donovani chromosome 34, encoding for a 636-amino acid polypeptide with an estimated molecular mass of 73 kDa. This subunit contains a sequence resembling the core domain of human topoisomerase I (hTopI from now) and conserves the catalytic “tetrad”: Arg-314, Lys-352, Arg-410 and His-453. LdTopIS, the gene encoding for the small subunit, is found on L. donovani chromosome 4 and encodes for a 262-amino acid polypeptide with a predicted molecular mass of 28-kDa. The small subunit includes the “SKXXY” signature placed at the C-terminal domain of all type I DNA topoisomerases, which conserves a tyrosine residue playing role in DNA cleavage. Gene silencing studies carried out with the Trypanosoma brucei bi-subunit topoisomerase IB reveals that both subunits are required for parasite survival .
The structural differences between human and kinetoplastid type IB DNA-topoisomerases make this enzyme an attractive target for chemotherapeutic intervention –. Topoisomerase inhibitors fall into two general categories: compounds that stimulate the formation of covalent enzyme-DNA complexes or topoisomerase poisons (class I inhibitors), and products that interfere with the enzymatic functions of the enzyme (class II inhibitors). Camptothecin (CPT) is a good example of a class I topoisomerase poison. This compound has a strong anti-leishmanial effect in experimental trials  and some analogues are used for the treatment of cancer (see the recent review by Pommier ). CPT is an uncompetitive inhibitor which, by binding covalently to DNA, traps the enzyme in an immobile ternary complex, preventing the DNA religation step. CPT generates covalent DNA-topoisomerase complexes with both nuclear and kinetoplastic preparations of DNA from trypanosomes, leishmanias  and other protozoan parasites of medical importance .
Previous studies have shown that the proteolytic cleavage of core and catalytic domains in hTopI within the non conserved linker domain did not affect markedly catalysis. Stewart and co-workers  reconstituted the relaxation activity of human topoisomerase by adding to the core domain a series of peptides containing the C-terminal domain, in a proportion of 1∶1 in the presence of DNA. This finding was reinforced by Park and Sternglanz  using a two-hybrid expression system. The authors identified proteins containing part of the linker and the C-terminal domain that supplemented the catalytic core of Saccharomyces cerevisiae topoisomerase I (yTopI).
The objective of this study is to find out structural insights within the C-extension end of the large subunit needed for a functional interaction with the small subunit. Our findings reveal that 75 residues placed at the C-terminal end of LdTopIL and 169 residues placed at the N-terminal extension of LdTopIS are dispensable for topoisomerization of supercoiled DNA.
Materials and Methods
Reagents and culture media
DNA modification and restriction enzymes were provided from Roche (Basel, Switzerland) and Amersham Biosciences. Pyrococcus furiosus (Pfu) polymerase was from Stratagene (La Jolla, CA, USA). Cell culture media, CPT and other chemicals and reagents were purchased from Sigma (St. Louis, MO). Primers for PCR amplification were from Sigma Genosys (UK).
Yeast and leishmanial strains
S. cerevisiae strains for protein expression: EKY3 [MAT α ura3-52 his3Δ200 leu2Δ1 trp1Δ63 TopIΔ::TRP1] and MBY3 [MAT α ura3-52 his3Δ200 leu2Δ1 trp1Δ63, TopIΔ::TRP1 rad52 Δ::LEU2], both lacking topoisomerase activity, were generously gifted by Dr. MA Bjornsti (St. Jude Children's Research Hospital, Memphis, TN) . Leishmania donovani promastigotes (LEM75, Ethiopian) were kindly supplied by Dr. J.M. Requena (Centro de Biología Molecular “Severo Ochoa”, CSIC Madrid, Spain).
Cloning of leishmanial DNA topoisomerase I
Cloning of heterodimeric LdTopIL/S was performed as described previously . LdTopIL (GenBank #AF303557) gene, was obtained by the screening of a λ-EMBL3 genomic library  whereas gene encoding the small subunit, LdTopIS (GenBank # AY062908) was amplified using primers based on L. major Friedlin genome Project and L. donovani genomic DNA as template .
C- and N-terminal truncations of LdTopIL/S
The different constructs were obtained by cloning the distinct PCR fragments in the bis-cistronic vector pESC -URA using current molecular biology techniques. The restriction sites for LdTopIL gene were BamH I and Xho I, whereas Not I and Spe I were chosen for LdTopIS gene. Figure 1 (A and B) shows the lineal structure of the bi-subunit LdTopIL/S, describing the different truncations performed on LdTopIL and LdTopIS subunits (scheme is not at scale).
A) Deletions performed on gene encoding for LdTopIL were LdTopIΔL at the N-terminal end, and LdTopIΔ467L, LdTopI490L, and LdTopI519L at the C-terminal end. These four deletions were cloned together with LdTopIS into the biscistronic pESC -URA for expression in S. cerevisiae. Six micrograms of yeast extracts were assayed in a plasmid DNA relaxation assay for 30 min at 37°C (as described under “Experimental Procedures”). Reaction products were resolved in agarose gel and subsequently visualized by ethidium bromide staining. The relative position of the negatively supercoiled DNA substrate is indicated by Sc, whereas the ladder of relaxed DNA topoisomer bands is labeled R. B) Scheme of the LdTopIL and LdTopIS deletions made on the non conserved extensions of each subunit and the combinations made between them. Deletions were named according to the amino acid position where the protein was truncated. Distances represented in the drawings are not in scale. C) 10% SDS-PAGE showing the purity of the different truncations used in the study.
The sequence of the primers used for gene amplification and their positions are listed in Table 1. The PCR reaction contained 20 ng of plasmid pSK-LdTopIL or pSK-LdTopIS as template, 250 ng of each oligonucleotide, 100 µM dNTPs, 5 µl of 10×Pfu buffer and 2.5 units of Pfu-polymerase for a total volume of 50 µl. The cycle was composed by a 5 min step at 94°C, followed by 29 cycles at 94°C for 1 min, 66°C for 1 min and 72°C for 1 min and ending with 10 min at 72°C. The genes were subcloned into the BamHI/XhoI sites for the LdTopIL subunit and NotI/SpeI for LdTopIS in the yeast expression vector pESC -URA under control of promoters GAL1 and GAL10 respectively.
Yeast expression system
S. cerevisiae strains EKY3 and MBY3 were transformed with the constructs showed in Figures 1 and 2, using the lithium acetate method . The promoted GAL expression vectors carrying the URA3 selection marker were maintained by selection in synthetic complete S.C. uracil- media. At least four independent clones were selected from each transformation. Prior to the 6-h induction with 2% galactose, each starter culture was incubated in SC ura- 2% raffinose medium to eliminate any traces of glucose that might inhibit the GAL promoter expression. The cells were harvested by centrifugation, washed and resuspended in TEEG buffer (50 mM Tris-HCl pH 7.4, 1 mM EDTA, 1 mM EGTA, 10% glycerol) supplemented with 0.2 M KCl and protease inhibitors cocktail [0.1 mg/ml sodium fluoride, 0.8 mg/ml sodium bisulphite, 2×Complete Mini® (Roche Molecular Biochemicals)]. Cell extracts were prepared by disruption with acid-washed glass beads according to a previously described procedure . Briefly, cells were subjected to one freeze/thaw cycle at −80°C, lysed by vortexing with 425–600 µm glass beads and the extracts were cleared by centrifugation at 15000×g for 30 min at 4°C.
A) Protein-dilution relaxation assay of LdTopIΔL/ΔS truncation (lanes 7 to 12) compared to wild type (lanes 1 to 6). 0.2 Micrograms of purified protein and a two-fold dilution series were incubated with 0.3 µg of RfI Φ X174 supercoiled DNA for 30 min at 37°C. B) Spot tests showing the sensibility to CPT of MBY3 yeast strain transformed with the “empty” pESC-URA vector (“mock”) or carrying the wild type or the double deletion LdTopIΔL/ΔS Exponentially growing cells in glucose, previously transformed with vectors carrying the corresponding topoisomerase encoding genes, were serially 10-fold diluted starting from OD595 = 0.3. Five microliters were spotted on selective media under repressed (2% glucose) or induced (2% galactose) conditions, in the presence or absence of 15 µM and 30 µM CPT. “Mock” assays were performed under similar assay conditions using the pESC -URA vector without any insert C) Dose-response curves of these transformed yeast to different concentrations of CPT. A, B and C are pictures representatives of multiple experiments. D is the average of four independent experiments.
The yeast cultures expressing different deletions were harvested, washed and disrupted as above. The cell extracts were subjected to double-ammonium sulfate fractionation (35 and 75% saturation) and the supernatant from the second precipitation was loaded onto a phosphocellulose (P-11) column. The recombinant proteins (wild-type and truncations) were eluted at 4°C with a discontinuous gradient of KCl (0.2, 0.4, 0.6, 0.8 and 1 M) in TEEG buffer, supplemented with 0.1 mg/ml sodium bisulphite, 0.8 mg/ml NaF and 0.2× protease inhibitors cocktail. The active fractions were loaded onto a phenyl-sepharose column and eluted with a discontinuous inverse gradient of KCl (1, 0.8, 0.6, 0.4 and 0.2 M). In order to reach an appropriate concentration for the different in vitro assays, the eluate from the phenyl-sepharose column was concentrated by Microcon YM-30 (Millipore®). To store it, 40% glycerol was added to preserve the activity and to keep in a −20°C freezer. Protein was determined by the Bradford method .
DNA relaxation assays
DNA topoisomerase I activity was assayed by the relaxation of negatively supercoiled plasmid DNA. The reaction mixture in a total volume of 20-µl contained 0.3 µg of supercoiled Rf I ΦX 174 DNA, 10 mM Tris-HCl buffer pH 7.5, 5 mM MgCl2, 0.1 mM EDTA, 15 µg/ml bovine serum albumin, 50 mM KCl and various concentrations of truncated specimens or wild type proteins. The reaction mixtures were incubated for 30 min at 37°C and stopped adding up to 1% SDS. The enzyme was digested with the addition of 2 µg of proteinase K, incubating for 1 h. The extent of plasmid DNA relaxation was assessed by electrophoresis in a 1% agarose gel in 0.1 M Tris borate EDTA buffer pH 8.0 at 2 V/cm for 14 h. The gels were visualized under UV illumination after being stained with ethidium bromide (0.5 mg/ml) and a posterior electrophoresis in the presence of 0.1 mg/ml ethidium bromide, in order to separate the relaxed topoisomers from the nicked forms .
Leishmania donovani DNA-topoisomerase IB (LdTopIL/S)
According to previous reports, LdTopIL/S was cloned, functionally expressed and purified using a yeast heterologous system . The linear schematic representation of Fig 1A shows that LdTopIL contains a non-conserved N-terminal extension (startMet-Glu43), followed by a region which resembles the hTopI “core” domain (Arg44-Ser456). Beyond Ser456 the homology with hTopI is lost dramatically and a non conserved C-terminal extension (Val457-Val635) displays no apparent function in topoisomerase activity. This region however, contains a long tail enriched in lysine residues, which may be putative nuclear localization signals (NLS).
The small leishmanial subunit LdTopIS contains a large non-conserved N-terminal extension (startMet-Lys211) enriched in serine residues which precedes to a C-terminal end closely homologous to the highly conserved C-terminal TopIB domains in other eukaryotes.
Combinatorial expression of LdTopIL, LdTopIS deleted genes in a topoisomerase deficient yeast strain
In order to know the role played by the non-conserved extensions of both LdTopIL and LdTopIS in topoisomerization of supercoiled DNA, a gradual deletion approach was carried out. For this purpose gradually deleted LdTopIL genes were cloned into the pESC -URA multiple cloning site driven by GAL1 promoter, remaining the unchanged LdTopIS gene into the multiple cloning site driven by GAL10 promoter (Fig 1A). The truncated proteins encoded by these genes lack the 26 first amino acids from the N-terminal domain (LdTopIΔL from now on) and three increasing length segments from the C-terminal end called LdTopIΔ467L, LdTopIΔ490L and LdTopIΔ519L. Relaxation of supercoiled DNA using yeast extracts that express the above-mentioned genes showed that, with exception of LdTopIΔL, which conserved full enzymatic activity, the other three deletions expressed non active topoisomerase specimens and thereby the removed peptides were considered essential to unwind DNA or to keep both subunits together in the heterodimer.
A similar approach was carried out deleting peptide segments from the N-extension end of LdTopIS. In a very recent report, the authors showed those truncations missing the entire N-terminal extension (called truncation E210end) or containing a short coil portion of this region (called truncation E200end) lacked any identifiable topoisomerase characteristics, in terms of DNA relaxation or CPT sensitivity when co-expressed with the large subunit . A shorter 169 amino acids truncation (LdTopIΔS from now on) was then designed. LdTopIΔS conserves the α-helix comprised between amino acids 190 to 208 intact, and an extra sequence which has no identifiable spatial arrangement (amino acids 169 to 189). This truncated protein relaxed supercoiled DNA at similar extent that wild type and was inhibited by CPT (data not shown).
Selection of functional topoisomerase truncations
Once regions involved in DNA relaxation were delimited within each enzymatic subunit, we proceeded to purify active truncated proteins with no distinguishable topoisomerase activity from wild type using large scale yeast cultures as described in Materials and Methods (Fig 1 B, C).
In a first approach we determined the activity of single truncations at N-terminal end of each subunit. 0.2 µg of each LdTopIΔL/S and LdTopIL/ΔS truncations and two-fold serially dilutions were assayed using 0.3 µg of supercoiled close circular DNA from the virus ΦX-174 (Rf I) DNA as substrate. No differences were found between these enzymatic specimens and wild-type in terms of topoisomerase activity (data not shown).
The combinatory expression of both deleted genes LdTopΔL/ΔS, served to generate a double truncated protein from EKY3 yeast deficient strain. After induction with galactose and purification according to the methods previously described, a relaxation assay was performed under the standard assay conditions, using similar protein concentrations of the purified wild type topoisomerase as relaxation control. Fig. 2A shows no differences in relaxation activities and distributive pattern between this double truncation and the wild type. For these reasons this protein specimen was used as minimal structure for further deletion studies into the large subunit.
We have analyzed the effect of CPT on a yeast-deficient topoisomerase I strain (MBY-3: TopI Δ::TRP1 rad52 Δ::LEU2) transfected with the bidirectional pESC -URA plasmid bearing the combination of double deleted LdTopIL and LdTopIS genes. Spot tests depicted in Fig. 2B show that after 2% galactose induction, CPT was as lethal for the cultures transformed with deletions LdTopIΔL/ΔS as for the wild type. Yeasts transformed with the “empty” vector (“mock”) were used as control, showing no response to CPT. These results agree well with the relaxation assays, showing that topoisomerase specimens expressed by yeasts were functional in vivo.
Searching for a minimal structure in LdTopIL
Once the double LdTopIΔL/ΔS truncation showed no differences in relaxation activity with respect to the wild type phenotype, a further gradual deletion study was carried out in the C-extension end of LdTopIL. It had been established from the results of Fig. 1 that yeasts transformed with deletions containing up to 52 amino acids upwards the end of the putative “core” domain, were not able to relax supercoiled DNA in a standard DNA-relaxation assay. It seems obvious that the amino acids comprised in this region (Gln-467 to Glu-519) should be relevant for enzyme integrity and thereby the truncations performed in this second study might contain them. The new topoisomerase specimens prepared within the region comprised between Ala548 to the protein end were: LdTopIΔ548ΔL, LdTopIΔ561ΔL and LdTopIΔ575ΔL, respectively and served to narrow the region involved, in any extent, in topoisomerization or protein-protein binding. These constructs were cloned together with LdTopIΔS deletion in the biscistronic pESC -URA vector, expressed and purified from EKY3 transformed yeast according to the above-mentioned method.
LdTopIΔ548ΔL/ΔS conserves a 18 amino acids length α-helix (Glu520 to Val538) which resembles the secondary structure of yeast topoisomerase I and a putative NLS (Arg476 to Lys491). Figure 3A shows the activity of the truncation LdTopIΔ548ΔL/ΔS in a DNA relaxation assay using similar conditions to those employed in Fig. 2. It is remarkable a weak but clear relaxation activity, as well as a slow appearing of DNA topoisomers detected in time-course experiments (Fig. 3B). Spot test experiments show however, no differences between LdTopIΔ548ΔL/ΔS and wild type in CPT sensitivity (Fig 3C), data which were reinforced in dose-response experiments (Fig 3D). Altogether it can be concluded that despite LdTopIΔ548ΔL/ΔS is a very weak active protein in relaxing supercoiled DNA, it is a DNA-cleaving enzyme and thereby susceptible to be poisoned by CPT.
A) Two-fold serial dilutions of the triple truncation LdTopIΔ548ΔL/ΔS were assayed in a plasmid DNA relaxation assay for 30 min at 37°C. B) Time-course experiment of topoisomerase activity using 0.2 µg of truncation LdTopIΔ548ΔL/ΔS per reaction 0.2 Micrograms of purified protein and a two-fold dilution series were incubated with 0.3 µg of RfI Φ X174 supercoiled DNA for 30 min at 37°C. Relaxation rate was compared with lane RfII which includes 0.3 µg of Φ X174 relaxed DNA C) Spot tests showing the sensibility to CPT of MBY3 yeast strain transformed with the “empty” pESC-URA vector (“mock”) or carrying the wild type LdTopIL/S genotype and deletion LdTopIΔ548ΔL/ΔS D) Dose-response curves of these transformed yeast to different concentrations of CPT. A, B and C are pictures representatives of multiple experiments. D is the average of four independent experiments.
LdTopIΔ561ΔL/ΔS is an intermediary 14 amino acids longer which displays a putative NLS. Time-course (Fig. 4B) and protein-dilution assays (Fig. 4A) carried out with purified truncated protein show slow but detectable topoisomerase activity. Spot test (Fig 4C) and dose-response (Fig 4D) experiments show no differences in CPT sensitivity respect wild type, suggesting that DNA-cleaving activity of this truncation is very likely. Finally LdTopIΔ575ΔL/ΔS (Fig. 5) was performed in order to assign a role to two lysine-enriched regions (Lys549 to Leu565 and Lys576 to Glu592) mostly arranged in α-helix and with putative NLS motifs (according to PSORT-II on-line software). Protein dilution (Fig. 5A) and time-course (Fig. 5B) assays show no differences in relaxation activity between them and a similar CPT sensitivity than the wild type (Fig. 5C and 5D), suggesting that these regions are disposables for activity although it may be relevant to drive the enzyme to the nucleus compartment.
A) Two-fold serial dilutions of truncation LdTopIΔ561ΔL/ΔS were assayed in a plasmid DNA relaxation assay for 30 min at 37°C. B) Time-course experiment of topoisomerase activity using 0.2 µg of truncation LdTopIΔ561ΔL/ΔS per reaction C) Spot tests showing the sensibility to CPT of MBY3 yeast strain transformed with the “empty” pESC-URA vector (“mock”) or carrying the wild type LdTopIL/S genotype and deletion LdTopIΔ561ΔL/ΔS D) Dose-response curves of these transformed yeast to different concentrations of CPT. A, B and C are pictures representatives of multiple experiments. D is the average of four independent experiments. Relaxation rate was compared with lane RfII which includes 0.3 µg of Φ X174 relaxed DNA. The “c” lane corresponds to an activity control, using a commercial topoisomerase.
A) Protein dilution relaxation assay: Two-fold serial dilutions of truncation LdTopIΔ575ΔL/ΔS were assayed in a plasmid DNA relaxation assay for 30 min at 37°C. B) Time-course experiment of topoisomerase activity using 0.2 µg of truncation LdTopIΔ575ΔL/ΔS per reaction C) Spot tests showing the sensibility to CPT of MBY3 yeast strain transformed with the “empty” pESC-URA vector (“mock”) or carrying the wild type LdTopIL/S genotype and deletion LdTopIΔ575ΔL/ΔS D) Dose-response curves of these transformed yeast to different concentrations of CPT. A, B and C are pictures representatives of multiple experiments. D is the average of four independent experiments. Relaxation rate was compared with lane RfII which includes 0.3 µg of Φ X174 relaxed DNA. The “c” lane corresponds to an activity control, using a commercial topoisomerase.
The existence of an unusual heterodimeric type IB topoisomerase in trypanosomatids was pointed out by our group in 2003 using a genomic approach in L. donovani. Since then  several reports have confirmed the presence of multimeric topoisomerases in other trypanosomatids like Trypanosoma brucei  and T. cruzi (Trypanosoma cruzi Genome Project http://www.tigr.org/tdb/e2k1/tca1/). This remarkable finding confirmed the results obtained in a previous report describing a putative topoisomerase lacking the C-terminal domain in L. donovani  and indicated that the small subunit had been ignored in early studies . Once resolved the primary amino acidic sequence of both subunits, it is of a paramount importance to know how these monomers are assembled to build up a functional heterodimer displaying fully relaxation activity and susceptible to be inhibited by CPT. It is of interest therefore, to identify structural insights indispensable for protein-protein interaction between large and small subunits.
The alignment of the amino acid sequence of LdTopIL/S with the human counterpart as well as its crystalline configuration show that overall, structure and catalytic machinery of the human and leishmanial enzymes are conserved, despite the fact that one of them is a monomer and the other is a heterodimer . From this comparison it is very likely that the N-terminal and core domains are placed at the LdTopIL subunit and the C-terminal end within the small LdTopIS subunit. However, with the data managed at present, it is not easy to assign a putative linker domain to a particular region of the bi-subunit leishmanial enzyme. The importance of this region is not only due to be a simple connector between core and C-terminal domains , but it contributes to DNA binding and CPT inhibition, probably by slowing down the religation step of the nicking-closing reaction -.
The evidences presented here indicate that long extensions placed at C-terminal end of LdTopIL and at N-terminal end of LdTopIS, respectively are dispensable in terms of relaxation activity and sensitivity to CPT. Moreover, the combinatorial association of some of these truncations restored a fully active enzyme which retained unaltered the cleavage and religation functions associated to any topoisomerase, in similar terms of wild-type. Results obtained in the present work show that at least a 94 amino acids long C-extension comprised between Gln467 to Ala548, are required to retain measurable relaxation activity and CPT sensitivity. Despite this extension lacks of any amino acid clearly involved in relaxation activity, it conserves a high pI which would permits the ionic interaction with the small subunit to hold the subunits together  and a putative NLS, as well. Further sequential deletions of the amino acids placed between truncations LdTopIΔ561ΔL/ΔS and LdTopIΔ575ΔL/ΔS, sited at the C-terminal end of the large subunit, showed that they were unnecessary for topoisomerization, but they contained multiple putative NLSs required to drive the assembled protein to the nucleus. Due to these NLS signals are placed at the C-terminal extension of the LdTopIL subunit only, it is thereby very likely that the enzyme assembly takes place in the cytosol before translocation to the nuclear compartment .
With regards to the small subunit, the N-extension domain comprising the first 169 amino acids seems to be unnecessary for relaxation and CPT sensitivity. However a further truncation up to Asn210 led to a neglect of interaction between subunits and topoisomerase activity. From the results obtained in this paper we can conclude that this 169 N-terminal extension of LdTopIS is not required either for the interaction between monomers or relaxation and DNA cleavage activities. A recent report shows the existence of a RPPVVSR motif within the small subunit (amino acids 175 to 182) required for relaxation activity and CPT sensitivity, thereby a minimal putative linker should contains these amino acids to fulfill topoisomerase activity .
Strikingly the minimal combined truncation reconstituted LdTopIΔ548ΔL/ΔS fully conserved the sensitivity to CPT. According to these results it may stated that the sensitivity to this class I inhibitor resides into amino acids of the core and C-terminal domains as well as in the RPPVV motif contained into the N-terminal extension of the small subunit . Marquis and co-workers have shown that the resistance to CPT displayed by L. donovani LdRCPT.160 strain is mediated by two amino acid substitutions within the core domain of the large subunit (Gly185Arg and Asp325Glu) resulting from two single nucleotide mutations. In addition, authors observed a decrease in DNA relaxation, presumably due to the presence of these mutations .
Once the dispensable regions are delimited in both subunits, an essential question arises: what is the role of the long serine-enriched region placed at LdTopIS? It has been proposed that this region is suitable to phosphorylation and may participate in the proteolytic breakdown of the enzyme after CPT exposure . Post-translational down-regulation of the human enzyme occurs with the hyperphosphorylated enzyme and it is replication independent . Topoisomerase degradation by 26S proteasome may increase tolerance to DNA cleaving poisons  and facilitate the DNA repairing activity of tyrosyl phosphodiesterase .
Altogether this study gives structural insights of the role played by the C-extension end of the LdTopIL in its protein-to-protein interaction with the small LdTopIS to build up a fully functional enzyme. The heterodimeric nature of topoisomerase IB in trypanosomatids provides for functional complementation using individual truncated fragments. It is remarkable the lack of function played by at least 169 amino acids located within the N-terminal extension of LdTopIS, as well as those placed beyond Ala-548 of the large LdTopIL. Further truncation from the large subunit results in a stepwise loss of activity up to Glu-519, truncation deficient in relaxation activity at all. A very recent finding from another lab concluded that the amino acids 39–456 of large subunit and 210–262 of small subunit constitute the minimal interactive portion of the bi-subunit leishmanial enzyme conserving relaxation activity . However the authors fail in describing a true putative linker since the enzymatic activity of this enzymatic specimen is almost undetectable as well as its sensitivity to CPT.
This paper provides structural insights into the N- and C-extensions involved in the interaction between protomers to build up a fully active topoisomerase in Leishmania parasites. These elements are not only required to reconstitute a putative linker domain, but also contain unexplored nuclear driving signals and potential post-translational motifs for down-regulation. Only a deeper knowledge of the structural design of these non-conserved regions will help to a full understanding of topoisomerase mechanisms in these ancient eukaryotes.
Conceived and designed the experiments: RB RR. Performed the experiments: RD. Analyzed the data: RB RD RR YP. Contributed reagents/materials/analysis tools: RB DO. Wrote the paper: RB RD.
- 1. Murray HW, Berman JD, Davies CR, Saravia NG (2005) Advances in leishmaniasis. Lancet 366: 1561–1577.HW MurrayJD BermanCR DaviesNG Saravia2005Advances in leishmaniasis.Lancet36615611577
- 2. Balana-Fouce R, Reguera RM, Cubria JC, Ordonez D (1998) The pharmacology of leishmaniasis. Gen Pharmacol 30: 435–443.R. Balana-FouceRM RegueraJC CubriaD. Ordonez1998The pharmacology of leishmaniasis.Gen Pharmacol30435443
- 3. Reguera RM, Redondo CM, Gutiérrez de Prado R, Pérez-Pertejo Y, Balaña-Fouce R (2006) DNA topoisomerase I from parasitic protozoa: a potential target for chemotherapy. Biochim Biophys Acta 1759: 117–131.RM RegueraCM RedondoR. Gutiérrez de PradoY. Pérez-PertejoR. Balaña-Fouce2006DNA topoisomerase I from parasitic protozoa: a potential target for chemotherapy.Biochim Biophys Acta1759117131
- 4. Villa H, Otero Marcos AR, Reguera RM, Balaña-Fouce R, García-Estrada C, et al. (2003) A novel active DNA topoisomerase I in Leishmania donovani. J Biol Chem 278: 3521–3526.H. VillaAR Otero MarcosRM RegueraR. Balaña-FouceC. García-Estrada2003A novel active DNA topoisomerase I in Leishmania donovani.J Biol Chem27835213526
- 5. Bodley AL, Chakraborty AK, Xie S, Burri C, Shapiro TA (2003) An unusual type IB topoisomerase from African trypanosomes, Proc Natl Acad Sci USA 100: 7539–7544.AL BodleyAK ChakrabortyS. XieC. BurriTA Shapiro2003An unusual type IB topoisomerase from African trypanosomes,Proc Natl Acad Sci USA10075397544
- 6. Bakshi RP, Shapiro TA (2004) RNA interference of Trypanosoma brucei topoisomerase IB: both subunits are essential. Mol Biochem Parasitol 136: 249–255.RP BakshiTA Shapiro2004RNA interference of Trypanosoma brucei topoisomerase IB: both subunits are essential.Mol Biochem Parasitol136249255
- 7. Chessman SJ (2000) The topoisomerases of protozoan parasites. Parasitol Today 16: 277–281.SJ Chessman2000The topoisomerases of protozoan parasites.Parasitol Today16277281
- 8. Das A, Dasgupta A, Sengupta T, Majumder HK (2004) Topoisomerases of kinetoplastid parasites as potential chemotherapeutic targets. Trends Parasitol. 20: 381–387.A. DasA. DasguptaT. SenguptaHK Majumder2004Topoisomerases of kinetoplastid parasites as potential chemotherapeutic targets.Trends Parasitol.20381387
- 9. Balaña-Fouce R, Redondo CM, Pérez-Pertejo Y, Díaz-González R, Reguera RM (2006) Targeting atypical trypanosomatid DNA topoisomerase I. Drug Discov Today 11: 733–740.R. Balaña-FouceCM RedondoY. Pérez-PertejoR. Díaz-GonzálezRM Reguera2006Targeting atypical trypanosomatid DNA topoisomerase I.Drug Discov Today11733740
- 10. Proulx ME, Desormeaux A, Marquis JF, Olivier M, Bergeron MG (2001) Treatment of visceral leishmaniasis with sterically stabilized liposomes containing camptothecin. Antimicrob Agents Chemother. 45: 2623–2627.ME ProulxA. DesormeauxJF MarquisM. OlivierMG Bergeron2001Treatment of visceral leishmaniasis with sterically stabilized liposomes containing camptothecin.Antimicrob Agents Chemother.4526232627
- 11. Pommier Y (2006) Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 6: 789–802.Y. Pommier2006Topoisomerase I inhibitors: camptothecins and beyond.Nat Rev Cancer6789802
- 12. Bodley AL, Shapiro TA (1995) Molecular and cytotoxic effects of camptothecin, a topoisomerase I inhibitor, on trypanosomes and Leishmania. Proc Natl Acad Sci USA 92: 3726–3730.AL BodleyTA Shapiro1995Molecular and cytotoxic effects of camptothecin, a topoisomerase I inhibitor, on trypanosomes and Leishmania.Proc Natl Acad Sci USA9237263730
- 13. Bodley AL (1998) Effects of camptothecin, a topoisomerase I inhibitor on Plasmodium falciparum. Biochem Pharmacol 55: 709–711.AL Bodley1998Effects of camptothecin, a topoisomerase I inhibitor on Plasmodium falciparum.Biochem Pharmacol55709711
- 14. Stewart L, Ireton GC, Champoux JJ (1997) Reconstitution of human topoisomerase I by fragment complementation, J. Mol. Biol. 269: 355–372.L. StewartGC IretonJJ Champoux1997Reconstitution of human topoisomerase I by fragment complementation,J. Mol. Biol.269355372
- 15. Park H, Sternglanz R (1998) Two separate conserved domains of eukaryotic DNA topoisomerase I bind to each other and reconstitute enzymatic activity. Chromosoma 107: 211–215.H. ParkR. Sternglanz1998Two separate conserved domains of eukaryotic DNA topoisomerase I bind to each other and reconstitute enzymatic activity.Chromosoma107211215
- 16. Hann CL, Carlberg AL, Bjornsti MA (1998) Intragenic suppressors of mutant DNA topoisomerase I-induced lethality diminish enzyme binding of DNA. J Biol Chem 273: 31519–31527.CL HannAL CarlbergMA Bjornsti1998Intragenic suppressors of mutant DNA topoisomerase I-induced lethality diminish enzyme binding of DNA.J Biol Chem2733151931527
- 17. Sambrook J, Fritsch EF, Maniatis TMolecular Cloning A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989. J. SambrookEF FritschT. ManiatisMolecular Cloning A Laboratory Manual.Cold Spring Harbor, NYCold Spring Harbor Laboratory Press, 1989
- 18. Altschul SF, Madden TL, Schäffer AA, Zhang J, Zhang Z, et al. (1997) Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25: 3389–3402.SF AltschulTL MaddenAA SchäfferJ. ZhangZ. Zhang1997Gapped BLAST and PSI-BLAST: a new generation of protein database search programs.Nucleic Acids Res2533893402
- 19. Gietz RD, Schiestl RH (1991) Applications of high efficiency lithium acetate transformation of intact yeast cells using single-stranded nucleic acids as carrier. Yeast 7: 253–263.RD GietzRH Schiestl1991Applications of high efficiency lithium acetate transformation of intact yeast cells using single-stranded nucleic acids as carrier.Yeast7253263
- 20. Jazwinski SM (1990) Preparation of extracts from yeast. Methods Enzymol 182: 154–174.SM Jazwinski1990Preparation of extracts from yeast.Methods Enzymol182154174
- 21. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248–254.MM Bradford1976A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.Anal Biochem72248254
- 22. Thrash C, Voelkel K, DiNardo S, Sternglanz R (1984) Identification of Saccharomyces cerevisiae mutants deficient in DNA topoisomerase I activity. J Biol Chem 259: 1375–1377.C. ThrashK. VoelkelS. DiNardoR. Sternglanz1984Identification of Saccharomyces cerevisiae mutants deficient in DNA topoisomerase I activity.J Biol Chem25913751377
- 23. Diaz Gonzalez R, Perez Pertejo Y, Redondo CM, Pommier Y, Balana-Fouce R, et al. (2007) Structural insights on the small subunit of DNA topoisomerase I from the unicellular parasite Leishmania donovani. Biochimie. R. Diaz GonzalezY. Perez PertejoCM RedondoY. PommierR. Balana-Fouce2007Structural insights on the small subunit of DNA topoisomerase I from the unicellular parasite Leishmania donovani.Biochimie
- 24. Broccoli S, Marquis JF, Papadopoulou B, Olivier M, Drolet M (1999) Characterization of a Leishmania donovani gene encoding a protein that closely resembles a type IB topoisomerase. Nucleic Acids Res 27: 2745–2752.S. BroccoliJF MarquisB. PapadopoulouM. OlivierM. Drolet1999Characterization of a Leishmania donovani gene encoding a protein that closely resembles a type IB topoisomerase.Nucleic Acids Res2727452752
- 25. Das A, Mandal C, Dasgupta A, Sengupta T, Majumder HK (2002) An insight into the active site of a type I topoisomerase from the kinetoplastid protozoan Leishmania donovani. Nucleic Acid. Res. 30: 794–802.A. DasC. MandalA. DasguptaT. SenguptaHK Majumder2002An insight into the active site of a type I topoisomerase from the kinetoplastid protozoan Leishmania donovani.Nucleic Acid. Res.30794802
- 26. Davies DR, Mushtaq A, Interthal H, Champoux JJ, Hol WG (2006) The structure of the transition state of the heterodimeric topoisomerase I of Leishmania donovani as a vanadate complex with nicked DNA. J Mol Biol 357: 1202–1210.DR DaviesA. MushtaqH. InterthalJJ ChampouxWG Hol2006The structure of the transition state of the heterodimeric topoisomerase I of Leishmania donovani as a vanadate complex with nicked DNA.J Mol Biol35712021210
- 27. Porter SE, Champoux JJ (1989) The basis for camptothecin enhancement of DNA breakage by eukaryotic topoisomerase I. Nucleic Acids Res 11: 8521–8532.SE PorterJJ Champoux1989The basis for camptothecin enhancement of DNA breakage by eukaryotic topoisomerase I.Nucleic Acids Res1185218532
- 28. Stewart L, Ireton GC, Champoux JJ (1999) A functional linker in human topoisomerase I is required for maximum sensitivity to camptothecin in a DNA relaxation assay. J. Biol. Chem. 274: 32950–32960.L. StewartGC IretonJJ Champoux1999A functional linker in human topoisomerase I is required for maximum sensitivity to camptothecin in a DNA relaxation assay.J. Biol. Chem.2743295032960
- 29. Ireton GC, Stewart L, Parker LH, Champoux JJ (2000) Expression of human topoisomerase I with a partial deletion of the linker region yields monomeric and dimeric enzymes that respond differently to camptothecin. J Biol Chem 275: 25820–25830.GC IretonL. StewartLH ParkerJJ Champoux2000Expression of human topoisomerase I with a partial deletion of the linker region yields monomeric and dimeric enzymes that respond differently to camptothecin.J Biol Chem2752582025830
- 30. Marquis JF, Hardy I, Olivier M (2005) Topoisomerase I amino acid substitutions, Gly185Arg and Asp325Glu, confer camptothecin resistance in Leishmania donovani. Antimicrob Agents Chemother 49: 1441–1446.JF MarquisI. HardyM. Olivier2005Topoisomerase I amino acid substitutions, Gly185Arg and Asp325Glu, confer camptothecin resistance in Leishmania donovani.Antimicrob Agents Chemother4914411446
- 31. Desai SD, Liu LF, Vazquez-Abad D, D'Arpa P (1997) Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin. J Biol Chem 272: 24159–24164.SD DesaiLF LiuD. Vazquez-AbadP. D'Arpa1997Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin.J Biol Chem2722415924164
- 32. Pommier Y, Redon C, Rao VA, Seiler JA, Sordet O, et al. (2003) Repair of and checkpoint response to topoisomerase I-mediated DNA damage. Mutat Res 532: 173–203.Y. PommierC. RedonVA RaoJA SeilerO. Sordet2003Repair of and checkpoint response to topoisomerase I-mediated DNA damage.Mutat Res532173203
- 33. Desai SD, Li TK, Rodríguez-Bauman A, Rubin EH, Liu LF (2001) Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res 61: 5926–5932.SD DesaiTK LiA. Rodríguez-BaumanEH RubinLF Liu2001Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells.Cancer Res6159265932
- 34. Pommier Y (2004) Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle checkpoints. Curr Med Chem Anticancer Agents 4: 429–434.Y. Pommier2004Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle checkpoints.Curr Med Chem Anticancer Agents4429434
- 35. Bosedasgupta S, Das BB, Sengupta S, Ganguly A, Roy A, et al. (2007) Amino acids 39-456 of large subunit and 210-262 of small subunit constitute the minimal, functionally interacting fragments of the unusual heterodimeric topoisomerase IB of Leishmania. Biochem J.. S. BosedasguptaBB DasS. SenguptaA. GangulyA. Roy2007Amino acids 39-456 of large subunit and 210-262 of small subunit constitute the minimal, functionally interacting fragments of the unusual heterodimeric topoisomerase IB of Leishmania.Biochem J.